Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17348031 | 0.83 | DGAT1 (0.33) | DGAT1MAOAMAOB | |
| SCHEMBL6562049 | 0.81 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL8750078 | 0.79 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL8879857 | 0.79 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL1136775 | 0.78 | NOS1 (0.43) | DGAT1NOS1NOS3NOS2 | |
| SCHEMBL15324947 | 0.78 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL28705194 | 0.78 | DGAT1 (0.34) | DGAT1MAOAMAOBNOS1 | |
| SCHEMBL12317214 | 0.78 | NOS1 (0.43) | DGAT1NOS1NOS3NOS2 | |
| SCHEMBL6379683 | 0.78 | DGAT1 (0.34) | DGAT1CTSKMAOAMAOBNOS1 | |
| SCHEMBL1136772 | 0.78 | NOS1 (0.43) | DGAT1NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994019-A | Process for the preparation of (R) -2- ((R) -2' -amino-4 ',5' -dihydro-1 ' H-imidazol-4 ' -yl) -6-methylhept-5-enoate derivatives | 临沂大学 | 2024-11-22 | — | — | CN | claimed |
| CN-115028554-B | Guanfacine hydrochloride and preparation method thereof | 海南慧谷药业有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-110698413-B | Substituted pyrimidine derivative containing guanidyl, pharmaceutical composition thereof, and preparation method and application thereof | 中国海洋大学 | 2023-01-24 | — | — | CN | claimed |
| CN-115028554-A | Guanfacine hydrochloride and preparation method thereof | 广东科泰鼎润药业科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-112375055-A | Preparation method of eptifibatide key raw material L-high arginine | 宁夏蓝博思化学技术有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-112358423-A | Preparation and application of novel polypeptide guanidizing agent | 宁夏蓝博思化学技术有限公司 | 2021-02-12 | — | — | CN | claimed |
| CN-110698413-A | Substituted pyrimidine derivative containing guanidyl, pharmaceutical composition thereof, and preparation method and application thereof | 中国海洋大学 | 2020-01-17 | — | — | CN | claimed |
| CN-108869233-A | A kind of small-sized pressure stabilizing long axis Fire Fighting Pumps using novel coolant | 贝德科技有限公司 | 2018-11-23 | — | — | CN | claimed |
| CN-102753546-A | 5-membered heterocyclic derivatives and process for producing the same | ILDONG PHARM CO LTD | 2012-10-24 | — | — | CN | claimed |
| CN-102134210-A | Leonurine derivative and preparation method thereof | UNIV FUDAN | 2011-07-27 | — | — | CN | claimed |
| US-20260138957-A1 | UREA-LINKED 2-AMINOIMIDAZOLE DIMER POTENTIATORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-3597184-B1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2026-03-04 | — | — | EP | disclosed |
| US-12559461-B2 | Antibiotic adjuvant compounds | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3727435-B1 | BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR | UNIV CARNEGIE MELLON (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-0754184-A1 | CEPHALOSPORIN ANTIBIOTICS | Microcide Pharmaceuticals, Inc. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1996038450-A1 | CEPHALOSPORIN ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1995026966-A1 | CEPHALOSPORIN ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
| CN-1098722-A | Tricyclic quinoxalinedione derivatives | SUMITOMO PHARMA (JP) | 1995-02-15 | — | — | CN | disclosed |
| CN-1040582-A | New peptidase inhibitors | MERRELL DOW PHARMA (US) | 1990-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | DGAT1 4765/4885CTSK 1726/4885MAOA 1400/4885 |
| US-20260138957-A1 | UREA-LINKED 2-AMINOIMIDAZOLE DIMER POTENTIATORS | BCR, ATF1, O60361 | DGAT1 1457/4885CTSK 2801/4885MAOA 3523/4885 |
| US-12559461-B2 | Antibiotic adjuvant compounds | MYD88, TLR5, TLR4 | DGAT1 2854/4885CTSK 2764/4885MAOA 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.